Neuroleptic malignant syndrome (NMS) is a life-threatening reaction to antipsychotic medications that requires immediate hospital treatment. The single most important step is stopping the medication that triggered it. From there, treatment focuses on cooling the body, replacing fluids, and in severe cases, using specific medications to reverse muscle rigidity and restore normal brain signaling. Mortality rates have dropped significantly with earlier recognition, falling from historical estimates of 11% to 38% down to roughly 5% to 11% in more recent studies.
Recognizing NMS Before Treatment Begins
NMS typically develops within days to weeks of starting or increasing an antipsychotic medication, though it can also occur when someone abruptly stops a medication used for Parkinson’s disease. The hallmark features are a dangerously high fever, severe muscle rigidity (often described as “lead pipe” stiffness), altered mental status ranging from confusion to unresponsiveness, and unstable vital signs like a racing heart, swinging blood pressure, and heavy sweating.
These symptoms can escalate quickly. The intense, sustained muscle contraction generates enormous heat and breaks down muscle tissue, a condition called rhabdomyolysis. That muscle breakdown releases proteins into the bloodstream that can clog and damage the kidneys. This chain of events is why rapid treatment matters so much: every hour of delay increases the risk of organ damage.
Step One: Stop the Triggering Medication
Discontinuing the offending drug is the most critical intervention. In most cases, this means stopping an antipsychotic. If NMS was instead triggered by the sudden withdrawal of a Parkinson’s medication (a dopamine-boosting drug), the treatment is the opposite: restarting that medication to restore dopamine activity in the brain.
Simply stopping the drug won’t produce instant relief. Many antipsychotics are long-acting, and some are given as injections that release medication over weeks. This means the body may continue to be exposed to the drug even after it’s been discontinued, which is why aggressive supportive care in a hospital setting is essential while waiting for the drug to clear.
Supportive Care in the Hospital
The foundation of NMS treatment is aggressive supportive care, typically in an intensive care unit. This involves three priorities happening simultaneously: bringing the body temperature down, replacing lost fluids, and correcting electrolyte imbalances caused by the muscle breakdown and excessive sweating.
Cooling measures can include ice packs placed on major blood vessels (neck, armpits, groin), cooling blankets, and cold intravenous fluids. The goal is to lower core temperature quickly enough to prevent brain and organ damage from sustained high fever.
Fluid replacement is especially aggressive because of the rhabdomyolysis risk. When muscle tissue breaks down, it releases a protein called myoglobin that can destroy kidney cells. The primary defense is flooding the kidneys with fluid to keep them flushing out that protein. Treatment protocols often target a urine output of around 200 milliliters per hour, far higher than normal, to protect kidney function. This requires large volumes of intravenous saline, sometimes alternated with other solutions to keep urine chemistry in a range that prevents the myoglobin from crystallizing inside the kidneys.
Benzodiazepines (a class of sedative) are frequently used to manage agitation, which serves a dual purpose: calming the patient and reducing the muscle activity that generates heat and worsens rhabdomyolysis.
Medications for Severe Cases
When supportive care alone isn’t enough, two medications are most commonly used. They work through different mechanisms and are sometimes given together.
The first is a dopamine-boosting drug (bromocriptine) given by mouth or through a feeding tube. NMS is essentially caused by a sudden, severe blockade of dopamine signaling in the brain, so this medication works by pushing dopamine activity back up. It’s typically given every 8 to 12 hours, with the dose increased as needed.
The second is a muscle relaxant (dantrolene) that works directly on muscle fibers to break the cycle of rigidity and heat production. It can be given intravenously in acute situations, then switched to an oral form once the patient stabilizes. By relaxing the muscles, it reduces both the dangerous fever and the ongoing muscle breakdown that threatens the kidneys.
These medications are generally continued for days to weeks, depending on severity and how long the triggering antipsychotic remains in the body. Long-acting injectable antipsychotics, for example, may require a much longer treatment window than a pill that clears the system in hours.
Preventing Kidney Failure
Kidney protection deserves special attention because acute kidney injury is one of the most common and dangerous complications of NMS. The severe muscle rigidity and tremor generate massive amounts of heat and destroy muscle cells, flooding the bloodstream with debris that the kidneys must filter out.
Beyond aggressive fluid replacement, the medical team monitors kidney function closely through blood and urine tests. Key markers include levels of a muscle enzyme (creatine kinase, often dramatically elevated in NMS), potassium, calcium, and creatinine. No single lab value perfectly predicts who will develop kidney failure, so the overall clinical picture guides how aggressively fluids and other interventions are pushed. In severe cases where the kidneys begin to fail despite fluid therapy, temporary dialysis may be necessary.
How Long Recovery Takes
Most episodes of NMS resolve within 7 to 14 days once the triggering medication is stopped and treatment is underway. Recovery can take longer, sometimes several weeks, if the cause was a long-acting injectable antipsychotic, because the drug continues to release into the body well after the last injection.
During recovery, patients may experience lingering weakness, confusion, or difficulty with movement. The intensity of the episode matters: someone who developed significant rhabdomyolysis or kidney injury will have a longer recovery path than someone whose NMS was caught early and remained mild.
Mortality is higher among elderly patients and those with significant underlying health conditions. Even with modern treatment, reported mortality rates still range from roughly 10% to 20% in these higher-risk groups.
Restarting Antipsychotic Medication After NMS
Many people who develop NMS still need antipsychotic medication for their underlying psychiatric condition, which creates a difficult balancing act. The general approach is to wait at least two weeks after all NMS symptoms have fully resolved before considering any antipsychotic again. Some clinicians prefer to wait even longer.
When an antipsychotic is reintroduced, the strategy typically involves choosing a different medication than the one that triggered the episode, starting at the lowest possible dose, and increasing very slowly with close monitoring. Newer, second-generation antipsychotics are often preferred because they tend to have a somewhat lower risk of triggering NMS, though no antipsychotic is completely free of this risk. Anyone who has had NMS once is considered at increased risk of developing it again, so both the patient and their care team need to remain vigilant for early warning signs with any future antipsychotic use.